14 /100
LOW RISK
Score updated May 29, 2026

JANX — Janux Therapeutics, Inc. Dilution Risk Tracker

Track JANX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track JANX — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
0
📊 Float Risk
30
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for JANX.
🔔 Track JANX — Get forecast alerts →

💹 Market Data

Market Cap$898.91M
Shares Outstanding60.98M
Float39.20M
Cash$956.39M
Debt$21.57M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 3.4% shares (2025Q4 vs prior)
181 institutional holders · 64.68M shares
#1 RA CAPITAL MANAGEMENT, L.P. 11.19M shares
#2 JANUS HENDERSON GROUP PLC 5.35M shares
#3 BlackRock, Inc. 4.08M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest7.93M
Days to Cover7.4
% of Float20.2%
FINRA data as of Apr 30, 2026

📁 Recent SEC Activity

4 INSIDER TRANSACTION Feb 04, 2026
3 FORM3 Feb 04, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track JANX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking JANX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for JANX
📊 JANX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 JANX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.